공시 • Jan 02
ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGM ALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur. 공시 • May 02
ALR Technologies SG Ltd. announced delayed 20-F filing On 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. 공시 • Dec 28
ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023 ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity. 공시 • Mar 01
Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority Study ALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013. 공시 • Feb 11
ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human Initiatives ALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings. 공시 • Nov 11
ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes Singapore ALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well. 